Sign In
23 May 2012 07:00
For immediate release | 23 May 2012 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting in London later this morning.
Michael Gatenby, the Company's Chairman, will make the following comments:
"Trading in the first four months of 2012 has been in line with our expectations overall, with turnover of £14.3 million for the period. This figure does not include any fulfilment of the cyclical toxicology product contract, which is scheduled to get underway in the second half of 2012.
"Some short term supply issues affecting AnbesolTM and Ashton & ParsonsTM Infant Powders which are now largely resolved have been offset by a strong performance from the promoted products. The moving annual total of HydromolTM sales was £3.9 million at April 2012, 26% higher than a year earlier, and the moving annual total of ImmuCystTM sales reached £4.4 million, 18% higher.
"We continue to await developments in Ireland, where there is discussion underway about changes to pricing and where we expect a move towards generic substitution which could impact Nu-SealsTM sales.
"We have a healthy pipeline of acquisition opportunities and remain confident of bringing more transactions to completion in the near future."
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Richard Wright, Finance Director | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan | |
Corporate Broking: David Poutney |
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Follow the stocks
